AFP and hepatocellular carcinoma: In patients with BCLC A HCC the diagnostic benefit from C16Cer and S1P was even more substantial since additional 20 patients with AFP levels < 200 ng/ml (88.4%) could be identified by C16Cer and S1P (Supplementary Figure 4B, 4D).